Prof. Jonathan Lipson says that opioid manufacturer Endo’s bankruptcy litigation doesn’t seem to have any “highly visible bad guys,” a marked difference from cases like Purdue Pharma.
Published on August 25, 2022
Endo Follows Opioid Bankruptcy Playbook, With A Few Twists
